Skip to main content

Molecular Devices Cuts Q3 Revenue Guidance 8-12 Percent on Soft Sales

NEW YORK (GenomeWeb News) – Soft sales during the third quarter has forced Molecular Devices to cut its financial guidance for the period by between 8 percent and 12 percent, the company said today.
 
Molecular Devices said it now expects revenue for the three months ended Sept. 30 to be between $44 million and $46 million. In July the company said it expected to generate between $48 million and $52 million in the period.
 
Third-quarter 2005 revenues were $45.2 million.
 
Molecular Devices in July also cut its full-year 2006 guidance to between $190 million and $198 million from between $198 million and $206 million.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.